Axel Hoos

Chief Executive Officer
Scorpion Therapeutics, Inc.

Dr. Axel Hoos is CEO of Scorpion Therapeutics, a next-generation oncology company focused on precision medicine 2.0 with the potential to address many of the current white spaces in cancer care.

Previously, he served as Senior Vice President and Therapeutic Area Head of Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK) where he built GSK’s Oncology business. Before GSK, he was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS), where he lead the clinical development of the first FDA-approved checkpoint immunotherapy ipilimumab, and spearheaded the launch of Immuno-Oncology. Dr. Hoos further serves as a Director on the Board of TCR2, a cell therapy company, as Trustee on the Board of the Sabin Vaccine Institute, as member of CRI’s Scientific Advisory Council, and as chairman of the Cancer Immunotherapy Consortium (CIC).